← Back

Futura Medical

0.2100-93.5%1Y · GBX

Futura Medical plc is a pharmaceutical and healthcare company focused on sexual health. Its lead product is Eroxon, a topical treatment for erectile dysfunction, and it is also developing WSD4000 for female sexual dysfunction. The company operates in the United Kingdom, the European Union, the United States, and internationally. Incorporated in 2001, it is headquartered in Guildford, United Kingdom.

Country
Price · split & dividend adjusted
News & notes moving FUM.LSE
United StatesUnited KingdomPhilippinesGreece
FUM.LSE

Diversified Energy Agrees $1.8 Billion Permian Deal

Diversified Energy Company PLC has agreed its biggest-ever deal, paying $1.8 billion for Permian Basin producer Birch, a move expected to boost production by around 35%. In other corporate news, Galliford Try Holdings PLC has landed a £110 million contract to build a 23-kilometre pipeline for Severn Trent to improve water quality in the River Mease. Sunda Energy PLC saw a major upgrade at its Halcon prospect offshore the Philippines, now assigned 8 trillion cubic feet of gas resources, giving Sunda a net share of 3 Tcf. Rockfire Resources PLC reported promising early processing tests at its Molaoi zinc project in Greece, with ore classed as "Medium-Hard" and within normal grinding energy requirements. Solvonis Therapeutics PLC received a key European patent allowance for its PTSD drug candidate SVN-114, calling it a vital milestone. Futura Medical PLC has initiated a formal sale process for the business behind its Eroxon gel and raised £1.6 million to fund the process.
DEC · Capital · Positive Agreed its biggest-ever $1.8bn deal to buy Permian producer Birch, expected to boost production ~35%.
FUM.LSE · Capital · Neutral Initiated a formal sale process for the Eroxon business and raised £1.6m to fund it.
GFRD.LSE · Demand · Positive Landed a £110m contract to build a 23-km pipeline for Severn Trent.
ROCK.LSE · Technology · Positive Promising early processing tests at its Molaoi zinc project, ore classed Medium-Hard within normal grinding energy.
SNDA.LSE · Supply · Positive Major upgrade at its Halcon prospect, now assigned 8 Tcf gas resources with a net 3 Tcf share to Sunda.
SVNS.LSE · Regulation · Positive Received a key European patent allowance for its PTSD drug candidate SVN-114, a vital milestone.
Read original ↗
Yahoo Finance·33dRead more →
FUM.LSE▼

Powerhouse Energy CEO to step down as company nears first commercial revenues

Powerhouse Energy Group announced that CEO Paul Emmitt will step down in September, just as the company moves towards first commercial revenues. Non-executive chairman David Hitchcock will become executive chair until a new CEO is appointed, while Emmitt is expected to continue working with Engsolve on a technical consultancy basis. 2025 revenue jumped to £1.23 million, with losses narrowing. In other AIM news, Quantum Blockchain Technologies reported a 30% mining advantage in live testing for its Method C AI Oracle, though losses widened slightly; the company has since raised fresh cash and extended bond maturities. Futura Medical ended its US partnership with Haleon for erectile dysfunction treatment Eroxon, lining up a new distributor, with Haleon paying a $1.9 million termination fee. ATOME is continuing talks with Paraguay's government and state power firm ANDE to keep its green fertiliser project on track, noting that Villeta could become the country's biggest ever industrial investment. Shares in DeFi Development Corporation UK jumped 83% after it announced a rebrand to Cykel AI alongside a full boardroom overhaul, with new CEO Gerald Tritt taking the reins as the company repositions around artificial intelligence.
DFDV.LSE · Capital · Positive Rebrand to Cykel AI and boardroom overhaul, shares jumped 83%.
FUM.LSE · Demand · Negative Ended US partnership with Haleon for Eroxon, losing a key distribution channel.
PHE.LSE · Capital · Positive CEO stepping down as company nears first commercial revenues, with revenue up and losses narrowing.
QBT.LSE · Technology · Positive Reported 30% mining advantage in live testing for Method C AI Oracle.
HLN.LSE · Capital · Neutral Paid $1.9 million termination fee to end partnership; minor financial impact.
Read original ↗
Yahoo Finance·99dRead more →